2. シグナル伝達
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Antibody

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

ADC Antibody 関連製品 (123):

製品番号 製品名 製品効果 純度 構造式
  • HY-P991668
    PF-06688992 Antibody
    PF-06688992 Antibody is an antibody targeting GD3. PF-06688992 Antibody can be used for the synthesis of the antibody-drug conjugate PF-06688992 (HY-P991668).
    PF-06688992 Antibody
  • HY-P992488
    ZV05
    ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer.
    ZV05
  • HY-P992459
    SGM-101 Antibody
    SGM-101 Antibody is a chimeric monoclonal antibody targeting carcinoembryonic antigen (CEA). SGM-101 Antibody can serve as a tumor-specific fluorescent imaging probe after being covalently conjugated with the near-infrared fluorescent dye BM104. SGM-101 Antibody accumulates in CEA-positive tumor tissues via antigen-antibody specific binding, and emits near-infrared fluorescence to enable imaging of tumor lesions. SGM-101 Antibody can be used in research related to gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, peritoneal carcinomatosis, and liver metastases.
    SGM-101 Antibody
  • HY-P992166
    AB-004
    AB-004 is a humanized monoclonal antibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research.
    AB-004
  • HY-P991640
    Anti-TDGF1 antibody (huB3F6)
    Anti-TDGF1 antibody (huB3F6) (BIIB015 antibody) is a CHO-expressed human antibody that targets TDGF1. Anti-TDGF1 antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TDGF1 antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Anti-TDGF1 antibody (huB3F6) can be used for synthesis of ADCs.
    Anti-TDGF1 antibody (huB3F6)
  • HY-P992026
    ADV-101 Antibody
    ADV-101 Antibody is a monoclonal antibody inhibitor targeting IL-1RAP. ADV-101 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ADV-101. ADV-101 Antibody can be used to research related to cancer.
    ADV-101 Antibody
  • HY-P992130
    Rolditamig
    Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 (HER2) antibody. Rolditamig can be conjugated with an enzyme-cleavable linker and a topoisomerase I inhibitor to form the ADC TQB2102. Rolditamig is applicable to research on solid tumors such as HER2-positive breast cancer.
    Rolditamig
  • HY-P992322
    BAY-79-4620 Antibody
    BAY-79-4620 Antibody is a potent and selective CAIX antibody with a human CAIX Kd of 3.6 nM. BAY-79-4620 Antibody yields antibody-drug conjugate (ADC) through conjugating with Monomethyl auristatin E (HY-15162) via a self-immolative enzyme-cleavable linker. BAY-79-4620 Antibody can be used for the research of cervical carcinoma, non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, gastric carcinoma, prostate carcinoma.
    BAY-79-4620 Antibody
  • HY-P992350
    EBC-129 Antibody
    EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets CEACAM5 and CEACAM6 glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma.
    EBC-129 Antibody
  • HY-P992171
    ADCT-701 Antibody
    ADCT-701 Antibody is a humanized IgG1 antibody against hDLK-1 and an ADC antibody. ADCT-701 Antibody can be conjugated with the PBD dimer cytotoxin SG3199 (HY-101161) via the cleavable Val-Ala (HY-W007035) linker to construct the ADC ADCT-701. ADCT-701 Antibody can be used in the research of neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and rhabdomyosarcoma.
    ADCT-701 Antibody
  • HY-P991874
    AMG-224 Antibody
    AMG-224 Antibody is an anti-human BCMA IgG1 antibody. AMG-224 Antibody can generate antibody drug conjugate (ADC) (AMG 224) with a tubulin inhibitor Mertansine (HY-19792). AMG-224 Antibody can be used for the study of multiple myeloma.
    AMG-224 Antibody
  • HY-P991930
    ARX305 Antibody
    ARX305 Antibody is an anti-human CD70 antibody. ARX305 Antibody can generate antibody drug conjugate (ADC) (ARX305) with a potent microtubule inhibitor PEG4-aminooxy-MMAF (AS269) (HY-128968). ARX305 Antibody can be used for the study of multiple solid and hematological cancers.
    ARX305 Antibody
  • HY-P992467
    SOT102 Antibody
    SOT102 Antibody is an IgG1 monoclonal antibody targeting CLDN18.2, and the antibody of ADC SOT102. SOT102 Antibody binds selectively to CLDN18.2, and promotes internalization. SOT102 Antibody can be used for the research of cancer[2].
    SOT102 Antibody
  • HY-P991940
    JBH492 Antibody
    JBH492 Antibody is a humanized, Fc-silenced anti-CCR7 IgG1 antibody. JBH492 Antibody can generate antibody drug conjugate (ADC) (JBH492) with a maytansinoid microtubule DM4 (HY-12454). JBH492 Antibody can be used for the study of lymphoma.
    JBH492 Antibody
  • HY-P991906
    TRPH-222 Antibody
    TRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma).
    TRPH-222 Antibody
  • HY-P991294
    MGTA-117 Antibody
    MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy.
    MGTA-117 Antibody
  • HY-P992127
    Renditatug
    Renditatug (BAT8008 Antibody) is an antibody targeting TROP2. Renditatug can be used for the synthesis of ADC BAT8008. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
    Renditatug
  • HY-P992477
    TR1801 Antibody
    TR1801 Antibody is a c-Met/HGFR-targeting monoclonal antibody, and an antibody of ADC TR1801. TR1801 Antibody can be used for synthesis of ADCs.
    TR1801 Antibody
  • HY-P99271A
    Tisotumab (powder)
    Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors.
    Tisotumab (powder)
  • HY-P991989
    MRG004A Antibody
    MRG004A Antibody (HuSC1-39) is a monoclonal antibody inhibitor targeting tissue factor (TF). MRG004A Antibody can be used to synthesize the antibody-drug conjugate (ADC) MRG004A. MRG004A Antibody can be used to research related to cancer.
    MRG004A Antibody